Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 2
1983 22
1984 57
1985 67
1986 95
1987 77
1988 126
1989 174
1990 207
1991 248
1992 306
1993 273
1994 366
1995 507
1996 493
1997 472
1998 511
1999 564
2000 483
2001 521
2002 554
2003 517
2004 458
2005 609
2006 462
2007 365
2008 350
2009 353
2010 417
2011 380
2012 394
2013 375
2014 388
2015 446
2016 406
2017 376
2018 356
2019 354
2020 405
2021 382
2022 34
Text availability
Article attribute
Article type
Publication date

Search Results

13,197 results
Results by year
Filters applied: . Clear all
Page 1
Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Qi Q, Wang R, Liu L, Zhao F, Wang S. Qi Q, et al. Int J Clin Pharmacol Ther. 2015 Oct;53(10):803-10. doi: 10.5414/CP202396. Int J Clin Pharmacol Ther. 2015. PMID: 26329348 Review.
This study aims to evaluate the effectiveness and tolerability of esomeprazole and omeprazole in patients with gastroesophageal reflux disease (GERD). ...A significant difference between esomeprazole 20 mg and omeprazole 40 mg (RR=0.68, 95% CI [0.47, 0 …
This study aims to evaluate the effectiveness and tolerability of esomeprazole and omeprazole in patients with gastroesophagea …
Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.
Asghar W, Pittman E, Jamali F. Asghar W, et al. Daru. 2015 Nov 14;23:50. doi: 10.1186/s40199-015-0133-6. Daru. 2015. PMID: 26573220 Free PMC article.
BACKGROUND: Both omeprazole and its S enantiomer (esomeprazole) have been available and used to treat symptoms of gastroesophageal reflux disease (GERD) and conditions associated with excessive stomach acid secretion for more than a decade. Controversy exists over i …
BACKGROUND: Both omeprazole and its S enantiomer (esomeprazole) have been available and used to treat symptoms of gastroesopha …
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P Jr, Katz PO, Chen Y, Sostek M. Miner P Jr, et al. Am J Gastroenterol. 2003 Dec;98(12):2616-20. doi: 10.1111/j.1572-0241.2003.08783.x. Am J Gastroenterol. 2003. PMID: 14687806 Clinical Trial.
The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. ...On day 5, intragastric pH was maintained above 4.0 for a mean of 14.0 h with esomeprazole
The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, om
Reply.
Nieves JW, Perez MC, Metz DC, Hansen KE. Nieves JW, et al. Gastroenterology. 2019 Aug;157(2):586. doi: 10.1053/j.gastro.2019.06.006. Epub 2019 Jun 13. Gastroenterology. 2019. PMID: 31260666 No abstract available.
Reply.
Cluver C, Hannan N, Tong S. Cluver C, et al. Am J Obstet Gynecol. 2019 Feb;220(2):207. doi: 10.1016/j.ajog.2018.10.009. Epub 2018 Oct 10. Am J Obstet Gynecol. 2019. PMID: 30315783 No abstract available.
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG; Esomeprazole Study Investigators. Richter JE, et al. Am J Gastroenterol. 2001 Mar;96(3):656-65. doi: 10.1111/j.1572-0241.2001.3600_b.x. Am J Gastroenterol. 2001. PMID: 11280530 Clinical Trial.
Healing rates at wk 4 were 81.7% and 68.7%, respectively. Esomeprazole was superior to omeprazole for all secondary measures and had a similar safety profile. ...The tolerability and safety of esomeprazole are comparable to that of omeprazole. (Am...
Healing rates at wk 4 were 81.7% and 68.7%, respectively. Esomeprazole was superior to omeprazole for all secondary measures a …
Introduction.
Illueca M. Illueca M. J Pediatr Gastroenterol Nutr. 2015 Jul;60 Suppl 1:S1. doi: 10.1097/01.mpg.0000466914.65742.da. J Pediatr Gastroenterol Nutr. 2015. PMID: 26422092 No abstract available.
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ, Andersson TB, Ahlström M, Weidolf L. Li XQ, et al. Drug Metab Dispos. 2004 Aug;32(8):821-7. doi: 10.1124/dmd.32.8.821. Drug Metab Dispos. 2004. PMID: 15258107
With several systems for CYP2C19 activity (two marker reactions, S-mephenytoin 4'-hydroxylation and R-omeprazole 5-hydroxylation, tested in either human liver microsomes or recombinant CYP2C19), the five PPIs showed competitive inhibition of CYP2C19 activity with K(i) of 0 …
With several systems for CYP2C19 activity (two marker reactions, S-mephenytoin 4'-hydroxylation and R-omeprazole 5-hydroxylation, tes …
Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Abed MN, Alassaf FA, Jasim MHM, Alfahad M, Qazzaz ME. Abed MN, et al. Pharmacology. 2020;105(11-12):645-651. doi: 10.1159/000506232. Epub 2020 Apr 14. Pharmacology. 2020. PMID: 32289807
OBJECTIVE: The present study is designed to explore the possible antioxidant capability of different PPIs, including omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, in an aim to suggest an agent that, in addition to its acid-suppression proper …
OBJECTIVE: The present study is designed to explore the possible antioxidant capability of different PPIs, including omeprazole, e
13,197 results
You have reached the last available page of results. Please see the User Guide for more information.